Despite the widespread success and increasing popularity of GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro, public perception of individuals using these medications remains largely negative. This persistent stigma surrounding the drugs, often referred to as 'Ozempic stigma,' continues to affect users.
The drugs have achieved significant success in the market, yet Americans hold unfavorable views about the people who take them. The reasons behind this stigma and its impact on users are explored in a cover story for The Highlight's August issue, written by Dylan Scott. The piece also delves into whether these negative perceptions might begin to diminish as more individuals start using the medications.
The August issue of The Highlight also includes articles on tolerating uncertainty in a complex world, the potential implications of rent freezes for renters, positive trends in declining road fatalities, and the anticipated rise of wealth driven by artificial intelligence.